about
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell LineA novel synthetic androgen receptor ligand, S42, works as a selective androgen receptor modulator and possesses metabolic effects with little impact on the prostate.Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development.Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives.Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation.A higher score on the Aging Males' Symptoms scale is associated with insulin resistance in middle-aged men.Selective androgen receptor modulator S42 suppresses prostate cancer cell proliferation.HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells.HMGA1a Induces Alternative Splicing of the Estrogen Receptor-αlpha Gene by Trapping U1 snRNP to an Upstream Pseudo-5′ Splice Site.Expansion of transplanted islets in mice by co-transplantation with adipose tissue-derived mesenchymal stem cells.GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle CellsSelective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubesCombined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic miceCircular IRE-type RNAs of the NR5A1 gene are formed in adrenocortical cellsExtension of Survival in Bilaterally Adrenalectomized Mice by Implantation of SF-1/Ad4BP-Induced Steroidogenic Cells
P50
Q35800392-FB094409-74B3-4AFD-9FBB-04670BE544C0Q36153987-8B0C4152-AB9A-4DE6-8E84-F9A6F70361D7Q39783751-0D06E10F-F15D-4155-897A-30DE11C2D94BQ43023352-F211E818-11C3-423E-9B55-EC453223E57AQ43081720-50A74CA1-F599-4E0D-B7CC-0EBCE4A00088Q47129584-0E4A1273-3036-4A93-8E6F-8B21F893B0A6Q47605856-36A070F3-0AB5-4177-83E4-FFD57388D3CBQ47759900-C10B650B-0690-4D63-A639-7E4AEF8A5183Q49998922-90DADC36-2C33-4397-BF8E-A9131294D4DEQ52717896-81C4A5CC-D2A1-4495-93D7-59B584A2ABD8Q55254725-28DAFBD3-F7CA-4DAE-ABEC-8B2F64212DEBQ55443665-708467CB-F1DB-4347-845F-1D812576746FQ61804186-7750FF0E-33B9-4341-B819-A2B3A8DBFA73Q61816260-FF0B5AF1-830D-4DD2-A9EC-B34E0A2B0632Q64100428-BA6C400E-FB91-4445-8630-D2B539BC29D4Q92251150-7E27EE61-5F8B-4B83-BD55-31439B5FA8FAQ92718497-418180DE-7685-440D-BAD6-A56A81D14BA1
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Tomoko Tanaka
@en
Tomoko Tanaka
@nl
type
label
Tomoko Tanaka
@en
Tomoko Tanaka
@nl
prefLabel
Tomoko Tanaka
@en
Tomoko Tanaka
@nl
P31
P496
0000-0002-3826-3653